IP Library Granted Patent US 9,125,805
Granted Patent B2
US 9,125,805 · App. 13/829,937 · Granted Sep 8, 2015

Stable formulations for parenteral injection of small molecule drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,125,805
App. No.
13/829,937
Granted
Sep 8, 2015
Kind
B2
Abstract

Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 3 ml.

Claims (8)

1. A method for treating or preventing anxiety, muscle spasms, or seizures, the method comprising parenterally administering to a subject in need thereof a stable liquid formulation comprising: (a) a biocompatible solvent consisting of dimethylsulfoxide (DMSO) or a mixture of DMSO and n-methyl pyrrolidone (NMP); and (b) a small molecule drug, or a salt thereof, solubilized within the solvent, wherein the small molecule drug is diazepam, and wherein diazepam is present in the liquid formulation in an amount up to its solubility limit in the formulation, wherein the liquid formulation comprises less than 5% by weight residual water, and wherein a volume of the liquid formulation to be parenterally injected is 3 ml or less.

2. The method of claim 1 , further comprising the injectable volume within a device for dispensing the liquid formulation.

3. The method of claim 2 , wherein the device is a syringe, a pen injection device, an auto-injector device, an external or implantable pump, or a perfusion bag.

4. The method of claim 1 , wherein the liquid formulation comprises 50 mg/ml to 300 mg/ml of diazepam.

5. The method of claim 1 , wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 1 μl.

6. The method of claim 1 , wherein the volume of the liquid formulation to be parenterally injected is from 1 μl to 10 μl.

7. The method of claim 1 , wherein the volume of the liquid formulation to be parenterally injected is from 10 μl to 1 ml.

8. The method of claim 1 , wherein the liquid formulation is not diluted prior to administration.

Assignments (4)
REASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Mar 10, 2022
From: OXFORD FINANCE LLC
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 059358/0700 →
SECURITY INTEREST Recorded Mar 9, 2022
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LIMITED
To: HAYFIN SERVICES LLP
Reel/Frame 059552/0066 →
SECURITY INTEREST Recorded Sep 12, 2019
From: XERIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050362/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2013
From: PRESTRELSKI, STEVEN; SCOTT, NANCY
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 031287/0727 →